NEWSWIRETODAY Press Release& Newswire Distribution | HOME
MOST TRUSTED NEWSWIRE PRESS RELEASE DISTRIBUTION
PRTODAY / NewswireToday press release distribution service network
Written by / Agency / Source: Histogen, Inc.
Check Ads Availability|e-mail Article

Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!

Secure Medical CEO John Rao Joins Histogen Board of Directors - Histogen, Inc., today announced that John Rao, founder and CEO of Secure Medical Inc., a medical technology company, has joined Histogen’s Board of Directors
Secure Medical CEO John Rao Joins Histogen Board of Directors

 

NewswireToday - /newswire/ - San Diego, CA, United States, 2008/05/09 - Histogen, Inc., today announced that John Rao, founder and CEO of Secure Medical Inc., a medical technology company, has joined Histogen’s Board of Directors.

   
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Pharma / BioTech / Nutrition Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

Histogen, Inc., a regenerative medicine company developing solutions based on the products of newborn fibroblasts, today announced that John Rao, founder and CEO of Secure Medical Inc., a medical technology company, has joined Histogen’s Board of Directors.

Within the medical field, Mr. Rao is an accomplished entrepreneur, innovator, and strong patient rights advocate, including his involvement with the American Telemedicine Association and his current patents relating to remote health kiosks and glyph identification. Mr. Rao founded Tempe-based Secure Medical in 1999 to bring healthcare services closer to patients through telemedicine, telehealth and telecare applications.

“John Rao’s background in technology innovation, and success within the medical industry, make him a prime addition to our Board of Directors,” said Dr. Gail Naughton, Histogen CEO and Chairman of the Board. “We look forward to tapping into John’s expertise as Histogen moves forward with manufacturing, research and development, and product launches.”

In addition to Secure Medical, Mr. Rao has owned and operated 14 technology-driven companies spanning a variety of industries including retail, wholesale, manufacturing and product development, as well as computer sciences and security driven methodologies. His passion for technology spans over 40 years, and he holds a number of patents and patent applications for innovative technologies.

“I am pleased to join Histogen’s Board of Directors, and excited to contribute to the Company’s success at this stage of tremendous growth,” said Rao. “Histogen’s unique technology platform, which has enabled the development of an extensive product portfolio from a single manufacturing process, gears the Company to become a leader in the industry.”

About Histogen

Histogen (histogeninc.com), launched in 2007, seeks to redefine regenerative medicine by developing a series of high value products without the use of embryonic stem cells or animal products. Through Histogen's proprietary bioreactors that mimic the embryonic environment, newborn fibroblasts are encouraged to naturally produce the vital proteins and growth factors from which the company has developed its rich product portfolio. Histogen has two product families – Exceltrix™, Histogen’s human Extracellular Matrix (ECM) and HGEN-001, Histogen’s proprietary liquid formula.

 
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Pharma / BioTech / Nutrition Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

Written by / Agency / Source: Histogen, Inc.

 
 

Availability: All Regions (Including Int'l)

 

Traffic Booster: [/] Quick NewswireToday Visibility Checker

 

Distribution / Indexing: [+]

 
 
# # #
 

 
  Your Banner Ad showing on ALL
Pharma / BioTech / Nutrition articles,
CATCH Visitors via Your Competitors Announcements!


Secure Medical CEO John Rao Joins Histogen Board of Directors

Company website links NOT available to basic submissions
It is OK to republish and/or LINK any newswire for any legitimate media purpose as long as you name NewswireToday and LINK as the source.
 
Publisher Contact: Eileen Naughton - HistogenInc.com 
 
Newswire Today - PRZOOM / PRTODAY disclaims any content contained in this article. If you need/wish to contact the company who published the current release, you will need to contact them - NOT us. Issuers of articles are solely responsible for the accuracy of their content. Our complete disclaimer appears here.
IMPORTANT INFORMATION: Issuance, publication or distribution of this press release in certain jurisdictions could be subject to restrictions. The recipient of this press release is responsible for using this press release and the information herein in accordance with the applicable rules and regulations in the particular jurisdiction. This press release does not constitute an offer or an offering to acquire or subscribe for any Histogen, Inc. securities in any jurisdiction including any other companies listed or named in this release.

Pharma / BioTech / Nutrition via RSSAdd NewswireToday - PRZOOM Headline News to FeedBurner
Find who RetweetFollow @NewswireTODAY

Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!


Read Latest Articles From Histogen, Inc. / Company Profile


Read Pharma / BioTech / Nutrition Most Recent Related Newswires:

Bruker’s Arxspan Business for Lab Informatics Expands Customer Capabilities by Joining Tetra Partner Network
Ipsen Announces Results from Phase III RESILIENT Trial Evaluating Onivyde® in Second-line Monotherapy for Small Cell Lung Cancer
Ipsen and Marengo Therapeutics Announce Strategic Partnership to Advance Two Precision Immuno-oncology Candidates from Marengo’s STAR Platform
SCHOTT Establishes Stand-alone Company for its Pharma Business to Promote Further Growth
Bushu Pharma Lauded by Frost & Sullivan for Enabling the Launch of Specialty Drugs in Japan and Asia-Pacific
BASF Expands World-scale Vitamin A Formulation Plant in Ludwigshafen
Ipsen to Acquire Epizyme, Expanding its Portfolio in Oncology
ANI Pharmaceuticals Adopts Veeva Commercial Cloud to Better Support Rare Disease Patients
GenScript ProBio and ProteoNic BV Signed a Strategic Cooperation Based on High Expressing Vector System
Ipsen Receives Positive Opinion in Europe for Dysport® in the Management of Urinary Incontinence in Adults
DSM Acquires Brazil’s Leading Animal Nutrition Technology Company to Boost Precision Services Offering
DSM and the World Food Programme Partner to Improve Nutrition Around the World
European Commission Approves Cabometyx® as A Second-line Treatment for People Living with Radioactive Iodine-refractory Differentiated Thyroid Cancer
Shionogi and NEC Enter into Strategic Research Collaboration for Novel Hepatitis B Therapeutic Vaccine
Boehringer Ingelheim Selects Veeva Development Cloud Worldwide to Bring Innovative Therapies to Patients Faster

Boost Your Social Network
& Crowdfunding Campaigns


LIFETIME SOCIAL MEDIA WALL
NewswireToday Celebrates 10 Years in Business


PREMIUM Members


Visit  BizJobs.com

Visit  La Bella Bakery Artisan Bakery Arizona





 
  ©2022 NewswireToday — Limelon Advertising, Co.
Home | About | Advertise/Pricing | Contact | Investors | Privacy/TOS | Sitemap | FRANCAIS
newswire, PR press releases distribution service magazines engine news alert newsroom press room breaking news public relations articles company news alerts newswiredistribution ezine bizentrepreneur biznewstoday digital business report market search pr firms agencies reports distri-bution today investor relation successful internet entrepreneurs newswire distribution prtoday.com newswiredistribution asianewstoday bizwiretoday USA pr UK today - NOT affiliated with PRNewswire as we declined their partnership offer in 2013
 
PRTODAY & NewswireTODAY are proudly NOT affiliated with USA TODAY (usatoday.com)